Biomedical Engineering Reference
In-Depth Information
73. Milojkovic D et al (2009) Mechanisms of resistance to imatinib and second-generation
tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 15:7519-7527
74. Wang X et al. (2008) Dasatinib pharmacokinetics and exposure-response (E-R): relationship
to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML). J Clin Oncol.
26 (No 15 S) (May 20 Suppl, Abstract 3590)
75. Mendel DB et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor
targeting vascular endothelial growth factor and platelet-derived growth factor receptors: deter-
mination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337
76. Faivre S et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel
oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35
77. Billemont B, et al. (2009) Correlation of sorafenib plasma concentrations and clinical toxic-
ity: a prospective population pharmacodynamic and pharmacokinetic study. J Clin Oncol 27
(No 15 S) (May 20 Suppl, e14585)
78. Ratain MJ et al (2007) The value meal: how to save $1,700 per month or more on lapatinib.
J Clin Oncol 25:3397-3398
79. Li J et al (2006) CYP3A Phenotyping approach to predict systemic exposure to EGFR
tyrosine kinase inhibitors. J Natl Cancer Inst 98:1714-1723
80. Martin P et al (2012) Pharmacokinetics of vandetanib: three phase I studies in healthy sub-
jects. Clin Ther 34(1):221-237
81. Zhang L et al (2011) Pharmacokinetics and tolerability of vandetanib in Chinese patients
with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clin Ther
33:315-327
82. Martin P et al (2011) Pharmacokinetic drug interactions with vandetanib during coadminis-
tration with rifampicin or itraconazole. Drugs R&D 11:37-51
83. Weil A et al (2010) Pharmacokinetics of vandetanib in subjects with renal or hepatic impair-
ment. Clin Pharmacokinet 49:607-618
84. Weisberg E et al (2007) Second generation inhibitors of BCR-ABL for the treatment of ima-
tinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7:345-356
85. Santos FP et al (2010) Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the poten-
tial treatment of leukemia. Curr Opin Investig Drugs 11:1450-1465
86. Keisner SV et al (2011) Pazopanib: the newest tyrosine kinase inhibitor for the treatment of
advanced or metastatic renal cell carcinoma. Drugs 71:443-454
87. Abbas R et al (2011) Pharmacokinetics of oral neratinib during co-administration of ketocon-
azole in healthy subjects. Br J Clin Pharmacol 71:522-527
88. Abbas R et al (2011) Effect of ketoconazole on the pharmacokinetics of oral bosutinib in
healthy subjects. J Clin Pharmacol 51:1721-1727
89. Jost LM et al (2006) Metabolism and disposition of vatalanib (PTK787/ZK-222584) in can-
cer patients. Drug Metab Dispos 34:1817-1828
90. Chiorean EG et al (2010) A phase I dose escalation and pharmacokinetic study of vatalanib
(PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors.
Cancer Chemother Pharmacol 66:441-448
91. Reardon DA et al (2009) Phase I pharmacokinetic study of the vascular endothelial growth
factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea
for malignant glioma. Cancer 115:2188-2198
92. Fox E et al (2010) A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavail-
able pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents
with refractory solid tumors. J Clin Oncol 28:5174-5181
93. Yamamoto N et al (2009) Phase I, dose escalation and pharmacokinetic study of cediranib
(RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients
with advanced solid tumors. Cancer Chemother Pharmacol 64:1165-1172
94. Goss G et al (2009) A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor
of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and
gemcitabine in patients with advanced non-small cell lung cancer: a study of the national
cancer institute of Canada clinical trials group. Eur J Cancer 45:782-788
